WO2015151080A3 - Specific conjugation of cell-binding molecules - Google Patents

Specific conjugation of cell-binding molecules Download PDF

Info

Publication number
WO2015151080A3
WO2015151080A3 PCT/IB2015/055051 IB2015055051W WO2015151080A3 WO 2015151080 A3 WO2015151080 A3 WO 2015151080A3 IB 2015055051 W IB2015055051 W IB 2015055051W WO 2015151080 A3 WO2015151080 A3 WO 2015151080A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell
binding molecules
specific conjugation
linkers
conjugates
Prior art date
Application number
PCT/IB2015/055051
Other languages
French (fr)
Other versions
WO2015151080A2 (en
Inventor
Robert Yongxin Zhao
Original Assignee
Suzhou M-Conj Biotech Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou M-Conj Biotech Co., Ltd filed Critical Suzhou M-Conj Biotech Co., Ltd
Priority to EP15772625.8A priority Critical patent/EP3317246A4/en
Priority to CA2991384A priority patent/CA2991384C/en
Priority to CN202110978276.7A priority patent/CN113698335A/en
Priority to CN201580082141.5A priority patent/CN108811499B/en
Priority to PCT/IB2015/055051 priority patent/WO2015151080A2/en
Priority to JP2017568455A priority patent/JP6700321B2/en
Publication of WO2015151080A2 publication Critical patent/WO2015151080A2/en
Publication of WO2015151080A3 publication Critical patent/WO2015151080A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/20—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a carbon atom of an acyclic unsaturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Cell binding agent-drug conjugates comprising bridge linkers, and methods of using such linkers and conjugates are provided.
PCT/IB2015/055051 2015-07-04 2015-07-04 Specific conjugation of a cell-binding molecule WO2015151080A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP15772625.8A EP3317246A4 (en) 2015-07-04 2015-07-04 Specific conjugation of a cell-binding molecule
CA2991384A CA2991384C (en) 2015-07-04 2015-07-04 Bridge linkers for conjugation of a cell-binding molecule
CN202110978276.7A CN113698335A (en) 2015-07-04 2015-07-04 Specific conjugation of cell binding molecules
CN201580082141.5A CN108811499B (en) 2015-07-04 2015-07-04 Specific conjugation of cell binding molecules
PCT/IB2015/055051 WO2015151080A2 (en) 2015-07-04 2015-07-04 Specific conjugation of a cell-binding molecule
JP2017568455A JP6700321B2 (en) 2015-07-04 2015-07-04 Specific conjugates of cell-binding molecules

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2015/055051 WO2015151080A2 (en) 2015-07-04 2015-07-04 Specific conjugation of a cell-binding molecule

Publications (2)

Publication Number Publication Date
WO2015151080A2 WO2015151080A2 (en) 2015-10-08
WO2015151080A3 true WO2015151080A3 (en) 2016-06-02

Family

ID=54241397

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2015/055051 WO2015151080A2 (en) 2015-07-04 2015-07-04 Specific conjugation of a cell-binding molecule

Country Status (5)

Country Link
EP (1) EP3317246A4 (en)
JP (1) JP6700321B2 (en)
CN (2) CN108811499B (en)
CA (1) CA2991384C (en)
WO (1) WO2015151080A2 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
ES2785551T3 (en) 2014-06-30 2020-10-07 Glykos Finland Oy Saccharide derivative of a toxic payload and its conjugates with antibodies
JP7330515B2 (en) * 2015-08-10 2023-08-22 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ． Novel conjugates and their use in specific conjugation of biomolecules and drugs
WO2015155753A2 (en) * 2015-08-10 2015-10-15 Suzhou M-Conj Biotech Co., Ltd Novel linkers and their uses in specific conjugation of drugs to a biological molecule
US11129910B2 (en) 2016-02-04 2021-09-28 Hangzhou Dac Biotech Co., Ltd. Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof
TWI808055B (en) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Combination therapies of hdac inhibitors and pd-1 inhibitors
TWI794171B (en) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Combination therapies of hdac inhibitors and pd-l1 inhibitors
IL263616B1 (en) 2016-07-07 2024-09-01 Univ Leland Stanford Junior Antibody adjuvant conjugates
CN106474147B (en) * 2016-10-14 2022-07-05 上海颉隆投资管理有限公司 Dressing for preventing and controlling human papilloma virus infection and preparation method thereof
AU2016429272A1 (en) * 2016-11-14 2019-05-02 Hangzhou Dac Biotech Co., Ltd. Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
CA3049926A1 (en) 2017-01-17 2018-07-26 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CN109444349B (en) * 2018-12-26 2020-07-07 中国科学院地球化学研究所 Method for measuring metabolic water utilization share and actual water demand of indoor plant
AU2020241686A1 (en) 2019-03-15 2021-11-04 Bolt Biotherapeutics, Inc. Immunoconjugates targeting HER2
CN111773183B (en) * 2019-04-04 2022-02-01 沈阳药科大学 Cu (DDC)2Nano nuclear liposome and preparation method and application thereof
MX2021013774A (en) 2019-05-14 2021-12-10 Nuvation Bio Inc Anti-cancer nuclear hormone receptor-targeting compounds.
IL289458A (en) 2019-06-29 2022-07-01 Hangzhou Dac Biotech Co Ltd Cell-binding molecule-tubulysin derivative conjugate and preparation method therefor
CN110308145A (en) * 2019-07-10 2019-10-08 迪瑞医疗科技股份有限公司 A kind of chlamydia trachomatis glycogen detection reagent, chlamydia trachomatis glycogen test strip and preparation method thereof
CN112341521B (en) * 2019-08-09 2024-06-25 上海翰森生物医药科技有限公司 Small molecule active compound and antibody conjugate thereof, preparation method and medical application thereof
US11952349B2 (en) 2019-11-13 2024-04-09 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CN110835405B (en) * 2019-11-28 2020-09-15 安阳师范学院 Polymer biosensor for tumor detection and preparation method and application thereof
CN111879684B (en) * 2020-06-18 2021-12-21 山东大学 Phagocyte function detection method based on flow cytometry
CN113925973A (en) * 2020-07-14 2022-01-14 辽宁中健医药科技有限公司 Polypeptide coupled drug, preparation method and application thereof
CN112409242B (en) * 2020-09-25 2022-07-12 华南农业大学 Amlodipine hapten, artificial antigen, antibody and preparation method and application thereof
CN112379029B (en) * 2020-11-10 2022-03-08 苏州艾迪迈医疗科技有限公司 Method for detecting concentration of anti-novel coronavirus drug in blood
CA3211696A1 (en) * 2021-02-23 2022-09-01 Children's Medical Center Corporation Intercellular adhesion molecule 1 (icam1) antibody drug conjugate and uses thereof
US11834458B2 (en) 2021-03-23 2023-12-05 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CN113214403B (en) * 2021-04-25 2023-06-09 重庆威斯腾前沿生物研究院有限责任公司 Streptavidin magnetic bead and preparation method thereof
JP2024516024A (en) 2021-05-03 2024-04-11 ニューベイション・バイオ・インコーポレイテッド Anti-cancer nuclear hormone receptor targeting compounds
CN113913535A (en) * 2021-11-30 2022-01-11 江西农业大学 Causal gene for identifying blue peacock white feather character and application thereof
WO2023125349A1 (en) * 2021-12-27 2023-07-06 山东先声生物制药有限公司 Anti-gucy2c antibody and application thereof
CN116239513B (en) * 2023-05-05 2023-08-18 天津凯莱英制药有限公司 Preparation method of MMAE key intermediate, preparation method of MMAE and antibody coupling drug
CN116813710B (en) * 2023-07-05 2024-07-12 重庆药友制药有限责任公司 Preparation method of carfilzomib

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101723961A (en) * 2009-12-08 2010-06-09 刘超美 Beta-lactam twin antibiotic compound, preparation method thereof and use thereof
WO2014080251A1 (en) * 2012-11-24 2014-05-30 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
WO2015028850A1 (en) * 2013-09-02 2015-03-05 Hangzhou Dac Biotech Co., Ltd Novel cytotoxic agents for conjugation of drugs to cell binding molecule

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0228358D0 (en) * 2002-12-05 2003-01-08 Unilever Plc Improvements relating to fabric treatment
SG189817A1 (en) * 2008-04-30 2013-05-31 Immunogen Inc Potent conjugates and hydrophilic linkers
EP2610263A1 (en) * 2011-12-30 2013-07-03 Brossmer, Reinhard Sialic acid dimers
CN103933575B (en) * 2013-01-23 2017-09-29 上海新理念生物医药科技有限公司 A kind of three flute profile connexons and its application
US11229711B2 (en) * 2013-06-06 2022-01-25 Magenta Therapeutics, Inc. Linkers for antibody-drug conjugates and related compounds, compositions, and methods of use
CN103467590B (en) * 2013-09-02 2016-04-13 深圳大学 Bioconjugation body, the purine compound preparing it, synthetic method, medicinal preparations and its application in immunomodulatory

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101723961A (en) * 2009-12-08 2010-06-09 刘超美 Beta-lactam twin antibiotic compound, preparation method thereof and use thereof
WO2014080251A1 (en) * 2012-11-24 2014-05-30 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
WO2015028850A1 (en) * 2013-09-02 2015-03-05 Hangzhou Dac Biotech Co., Ltd Novel cytotoxic agents for conjugation of drugs to cell binding molecule

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHARLTON, J. L. ET AL.: "Synthesis of chiral Esters of Acetylenedicarboxylic Acid", TETRAHEDRON LETTERS, vol. 35, no. 34, 22 August 1994 (1994-08-22), pages 6243 - 6246, XP055450908, ISSN: 0040-4039 *
HASHMI, A.S.K. ET AL.: "Photochemical Synthesis of Prochiral Dialkyl 3, 3- Dialkylcyclopropene-1, 2- dicarboxylates with Facial Shielding Substituents and Related Substrates", EUR. J. ORG. CHEM., 26 November 2001 (2001-11-26), pages 4705 - 4732, XP055450906, ISSN: 1434-193X *
HEYL, D. ET AL.: "Facile Direct Synthesis of Acetylenedicarboxamides", SYNTHESIS, vol. 46, no. 11, 17 March 2014 (2014-03-17), pages 1463 - 1468, XP055450898, ISSN: 0039-7881 *
MIKROYANNIDIS, J. A. ET AL.: "Synthesis, Photophysics, Structure-Tunable Photoluminescence, and Electrochemical Properties of Soluble Poly(p-phenylenevinylene)- Based Polymers with Adjacent 1, 3, 4-Oxadiazoles in the Backbone", JOURNAL OF POLYMER SCIENCE , PART A: POLYMER CHEMISTRY, vol. 43, no. 14, 31 December 2005 (2005-12-31), pages 3079 - 3090, XP055450904, ISSN: 0887-624X *
VAN WUYTSWINKEL, G. ET AL.: "A convergent synthesis of heterocyclic dendrimers using the 1, 3-dipolar cycloaddition reaction of organic azides and acetylenedicarboxylate esters", J. CHEM. SOC., PERKIN TRANS., vol. 1, no. 9, 10 April 2000 (2000-04-10), pages 1337 - 1340, XP055450907, ISSN: 1470-4358 *

Also Published As

Publication number Publication date
CA2991384A1 (en) 2015-10-08
WO2015151080A2 (en) 2015-10-08
JP6700321B2 (en) 2020-05-27
CN113698335A (en) 2021-11-26
CA2991384C (en) 2022-11-08
CN108811499A (en) 2018-11-13
JP2018523639A (en) 2018-08-23
EP3317246A2 (en) 2018-05-09
CN108811499B (en) 2021-09-24
EP3317246A4 (en) 2019-02-27

Similar Documents

Publication Publication Date Title
WO2015151080A3 (en) Specific conjugation of cell-binding molecules
WO2015151078A3 (en) Hydrophilic linkers for conjugation
EP3538080A4 (en) Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
EP3411074A4 (en) Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof
AU2018236742B2 (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
EP3801634A4 (en) Tumor microenvironment-activated drug-binder conjugates, and uses related thereto
EP3675892A4 (en) Immunostimulatory fusion molecules and uses thereof
EP3585424A4 (en) Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2
EP3541414A4 (en) Conjugated biological molecules, pharmaceutical compositions and methods
IL262396A (en) Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof
WO2017031458A3 (en) Anti-dll3 antibody drug conjugates and methods of use
EP3319936A4 (en) Bridge linkers for conjugation of cell-binding molecules
WO2018109170A3 (en) Il-11ra antibodies
MX2019006043A (en) Prostate specific membrane antigen binding protein.
WO2017173415A3 (en) Saccharide-polypeptide conjugate compositions and methods of use thereof
SG10201803042PA (en) Anti-tim-3 antibodies
EP3256495A4 (en) Compositions and methods for combination therapy with prostate-specific membrane antigen binding proteins
EP3450460A4 (en) Multi-specific binding conjugate, related pharmaceutical compositions and use
IN2015DN02577A (en)
EP3271329A4 (en) Novel hydrophilic linkers and ligand-drug conjugates thereof
EP3720842A4 (en) Acyl hydrazone linkers, methods and uses thereof
IL272931A (en) Peptide conjugates, conjugation process, and uses thereof
KR20220016865A9 (en) Antigen Binding Molecules, Pharmaceutical Compositions, and Methods
EP3519440A4 (en) Cmet monoclonal binding agents, drug conjugates thereof and uses thereof
IL269028A (en) Boronated multifunctional targeting drug conjugates, their uses and methods for their preparation

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2017568455

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2991384

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2015772625

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15772625

Country of ref document: EP

Kind code of ref document: A2